Brokerage firm Jefferies Assumes its rating on Aratana Therapeutics Inc(NASDAQ:PETX). The shares have been rated Buy. The rating by Jefferies was issued on Aug 19, 2016.
In a different note, On Aug 11, 2016, Barclays said it Maintains its rating on Aratana Therapeutics Inc. In the research note, the firm Lowers the price-target to $15.00 per share. The shares have been rated ‘Overweight’ by the firm.
Aratana Therapeutics Inc (PETX) made into the market gainers list on Mondays trading session with the shares advancing 3.20% or 0.29 points. Due to strong positive momentum, the stock ended at $9.36, which is also near the day’s high of $9.43. The stock began the session at $9.08 and the volume stood at 8,46,107 shares. The 52-week high of the shares is $19.9896 and the 52 week low is $2.56. The company has a current market capitalization of $331 M and it has 3,54,15,772 shares in outstanding.
Aratana Therapeutics Inc(PETX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $38.05M. Analysts had an estimated revenue of $7.61M. Earnings per share were $0.69. Analysts had estimated an EPS of $0.24.
Several Insider Transactions has been reported to the SEC. On Aug 10, 2016, Peter Steven St (PRESIDENT AND CEO) sold 50,000 shares at $9.25 per share price.Also, On Jun 28, 2016, Julia A Stephanus (CHIEF COMMERCIAL OFFICER) sold 30,000 shares at $6.25 per share price.On Jun 13, 2016, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $6.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.